AngioDynamics to Participate in Three Investor Conferences in March
Get Alerts ANGO Hot Sheet
Join SI Premium – FREE
LATHAM, N.Y.--(BUSINESS WIRE)-- AngioDynamics, Inc. (NASDAQ: ANGO), a leading and transformative medical technology company focused on restoring healthy blood flow in the body’s vascular system, expanding cancer treatment options and improving quality of life for patients, today announced that Jim Clemmer, President and Chief Executive Officer, and Stephen Trowbridge, Executive Vice President and Chief Financial Officer, will participate in the following three investor conferences in March:
Raymond James Institutional Investors Conference
Format: In-person Presentation
Date: Monday, March 6, 2023
Time: 8:05 a.m. ET
Location: Orlando, FL
Oppenheimer Virtual Healthcare Conference
Format: Fireside Chat
Date: Monday, March 13, 2023
Time: 9:20 a.m. ET
KeyBanc Virtual Life Sciences & MedTech Investor Forum
Format: Fireside Chat
Date: Tuesday, March 21, 2023
Time: 4:30 p.m. ET
A live webcast of each presentation will be accessible through the “Investors” section of the Company’s website at www.angiodynamics.com and will be available for replay following each event.
About AngioDynamics, Inc.
AngioDynamics is a leading and transformative medical technology company focused on restoring healthy blood flow in the body’s vascular system, expanding cancer treatment options and improving quality of life for patients.
The Company’s innovative technologies and devices are chosen by talented physicians in fast-growing healthcare markets to treat unmet patient needs. For more information, visit www.angiodynamics.com.
View source version on businesswire.com: https://www.businesswire.com/news/home/20230228005538/en/
Investor:
AngioDynamics, Inc.
Stephen Trowbridge, Executive Vice President & CFO
(518) 795-1408
Source: AngioDynamics, Inc.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Mirum Pharmaceuticals to Host Investor Call to Share Topline Results from the Phase 3 AZURE-1 Study of Brelovitug in Chronic Hepatitis Delta on September 28, 2026
- Sun Nuclear Announces Validated Adaptive QA Solution in Support of New Radiotherapy System, Accela, by Siemens Healthineers
- Next XRP? Remittix Combines PayFi Utility, BINANCE500 Rewards and an Official Token Launch Date
Create E-mail Alert Related Categories
Business Wire, Press ReleasesRelated Entities
KeyBanc, Raymond JamesSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!



Tweet
Share